Gastrointestinal Tolerance, Malnutrition, and Healthcare Resource Utilization are Impacted in Pediatric and Adult Outpatients using a Pea Peptide Enteral Formula
Authors: Vanessa Millovich1, Irene Olsen Shingara1, and Christina J. Valentine1
Research Presented as a Poster at the 2026 Annual Scientific Conference for The Professional Society for Health Economics and Outcomes Research (ISPOR)
Population and Design
Retrospective real-world evidence study of 1,208 children (1-17 years) and adults (≥18 years) conducted using a closed U.S. claims database. Pediatric and adult outpatients with a prescription claim for a nutrition formula were included.
Individuals consumed either organic pea peptide formulas (n=269) or casein/whey-based peptide formulas (n=939).
Outcomes Measured
Baseline risk of mortality (Charlson Comorbidity Index), malnutrition, weight loss, GI medication use, any GI intolerance (AGII) symptom score. Outcomes were evaluated by comparing unadjusted descriptive measures of 180 days pre-index and 90 days post-index.
Results
Patients on organic pea peptide formulas were sicker at baseline, with 50.3% having a CCI score ≥1 vs. 42.8% for those on dairy-based peptide formula.
Patients on organic pea peptide formulas had a 33.1% relative decrease in occurrence of any GI intolerance symptom reported from pre- to post-index compared to 23.5% for those on dairy-based peptide formulas.
Patients on organic pea peptide formulas had a 36.6% relative decrease in the rate of malnutrition from pre- to post-index compared to 21% for those on dairy-based peptide formulas.
Read Full-Text Poster from ISPOR 2026 Conference
Affiliations:
1. Kate Farms, Goleta, CA, United States
Citation:
Millovich V et al., 2026; Value Health, 29(6): S405
Loading form...
We'll have your form in just a moment